Isan Chen

12.1k total citations · 4 hit papers
41 papers, 9.1k citations indexed

About

Isan Chen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Isan Chen has authored 41 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Isan Chen's work include Prostate Cancer Treatment and Research (12 papers), Renal cell carcinoma treatment (11 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Isan Chen is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), Renal cell carcinoma treatment (11 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Isan Chen collaborates with scholars based in United States, Canada and Australia. Isan Chen's co-authors include Sindy T. Kim, M. Dror Michaelson, Ronald M. Bukowski, Thomas E. Hutson, Robert J. Motzer, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Piotr Tomczak and Robert A. Figlin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Isan Chen

39 papers receiving 8.9k citations

Hit Papers

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell... 2007 2026 2013 2019 2007 2009 2009 2013 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
    2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. New England Journal of Medicine profile →
  2. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
  3. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    2009 1.0k citations Richard S. Finn, Judy Dering et al. Breast Cancer Research profile →
  4. A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
    2013 455 citations James D. Joseph, Nhin Lu et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isan Chen United States 16 7.0k 4.8k 3.6k 3.1k 606 41 9.1k
Sindy T. Kim United States 16 8.4k 1.2× 5.9k 1.2× 4.6k 1.3× 3.9k 1.3× 774 1.3× 22 10.9k
Viktor Grünwald Germany 41 6.8k 1.0× 5.5k 1.2× 4.1k 1.1× 3.0k 1.0× 1.1k 1.8× 328 10.4k
Gary R. Hudes United States 40 6.8k 1.0× 6.1k 1.3× 3.5k 1.0× 3.6k 1.2× 1.2k 2.0× 102 10.7k
Wanling Xie United States 44 5.5k 0.8× 3.2k 0.7× 2.9k 0.8× 2.4k 0.8× 1.0k 1.7× 181 7.8k
Paul Bycott United States 24 4.5k 0.6× 3.7k 0.8× 2.9k 0.8× 2.2k 0.7× 567 0.9× 51 7.1k
Manuela Schmidinger Austria 33 5.4k 0.8× 3.9k 0.8× 3.0k 0.8× 2.3k 0.7× 1.1k 1.8× 180 8.5k
Sergio Bracarda Italy 38 7.6k 1.1× 5.8k 1.2× 4.4k 1.2× 3.8k 1.2× 2.1k 3.4× 236 11.6k
Tomasz Demkow Poland 21 4.3k 0.6× 3.6k 0.8× 2.2k 0.6× 2.3k 0.7× 773 1.3× 77 6.6k
Charles M. Baum United States 35 8.2k 1.2× 5.9k 1.2× 4.7k 1.3× 3.4k 1.1× 1.4k 2.4× 71 12.8k
Apurva A. Desai United States 21 4.0k 0.6× 3.9k 0.8× 2.5k 0.7× 2.2k 0.7× 454 0.7× 36 6.8k

Countries citing papers authored by Isan Chen

Since Specialization
Citations

This map shows the geographic impact of Isan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isan Chen more than expected).

Fields of papers citing papers by Isan Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isan Chen. The network helps show where Isan Chen may publish in the future.

Co-authorship network of co-authors of Isan Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Isan Chen. A scholar is included among the top collaborators of Isan Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isan Chen. Isan Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chepeha, Douglas B., Amy Prawira, Douglass Vines, et al.. (2019). Abstract CT124: Sitravatinib and nivolumab in oral cavity cancer window of opportunity study (SNOW). Cancer Research. 79(13_Supplement). CT124–CT124. 1 indexed citations
3.
Ingham, Matthew, et al.. (2017). Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma.. Journal of Clinical Oncology. 35(15_suppl). TPS11082–TPS11082. 3 indexed citations
4.
Nemunaitis, John, Hossein Borghaei, Wallace Akerley, et al.. (2017). P2.06-014 Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy. Journal of Thoracic Oncology. 12(1). S1078–S1078. 3 indexed citations
5.
Schwartz, Gary K., Douglas Adkins, Rebecca S. Heist, et al.. (2015). A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). TPS2621–TPS2621. 3 indexed citations
6.
Sonpavde, Guru, Gregory R. Pond, Andrew J. Armstrong, et al.. (2014). Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 12(5). 317–324. 63 indexed citations
7.
Joseph, James D., Nhin Lu, Jing Qian, et al.. (2013). A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509. Cancer Discovery. 3(9). 1020–1029. 455 indexed citations breakdown →
8.
Rathkopf, Dana E., Michael J. Morris, Josef J. Fox, et al.. (2013). Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 31(28). 3525–3530. 204 indexed citations
9.
Rathkopf, Dana E., Neal D. Shore, Emmanuel S. Antonarakis, et al.. (2012). A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 30(15_suppl). TPS4697–TPS4697. 15 indexed citations
10.
Rathkopf, Dana E., Michael J. Morris, Daniel C. Danila, et al.. (2012). A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 30(15_suppl). 4548–4548. 10 indexed citations
11.
Motzer, Robert J., Gary R. Hudes, Michelle S. Ginsberg, et al.. (2010). Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology. 33(6). 614–618. 22 indexed citations
12.
Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2009). Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(22). 3584–3590. 1711 indexed citations breakdown →
13.
Finn, Richard S., Judy Dering, Dylan Conklin, et al.. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research. 11(5). R77–R77. 1044 indexed citations breakdown →
14.
15.
Rini, Brian I., M. Dror Michaelson, Jonathan E. Rosenberg, et al.. (2008). Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 26(22). 3743–3748. 321 indexed citations
16.
Menu, Eline, Josefina García, Xiangao Huang, et al.. (2008). A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model. Cancer Research. 68(14). 5519–5523. 81 indexed citations
17.
Luo, Xuemei, Joseph C. Cappelleri, David Cella, et al.. (2008). Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy–Kidney Symptom Index—Disease-Related Symptoms Scale. Value in Health. 12(4). 580–586. 7 indexed citations
18.
Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2007). Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine. 356(2). 115–124. 4471 indexed citations breakdown →
19.
Menu, Eline, Josefina García, Xiangao Huang, et al.. (2007). Targeting CDK4/6 and the Cell Cycle in Combination with Bortezomib in the 5T33MM Myeloma Model.. Blood. 110(11). 254–254. 1 indexed citations
20.
Rini, Brian I., Vanessa Shaw, Jonathan E. Rosenberg, Sindy T. Kim, & Isan Chen. (2006). Patients with Metastatic Renal Cell Carcinoma with Long-Term Disease-Free Survival After Treatment with Sunitinib and Resection of Residual Metastases. Clinical Genitourinary Cancer. 5(3). 232–234. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sindy T. Kim Breakdown of academic impact, for papers by Viktor Grünwald Breakdown of academic impact, for papers by Gary R. Hudes Breakdown of academic impact, for papers by Wanling Xie Breakdown of academic impact, for papers by Paul Bycott Breakdown of academic impact, for papers by Manuela Schmidinger Breakdown of academic impact, for papers by Sergio Bracarda Breakdown of academic impact, for papers by Tomasz Demkow Breakdown of academic impact, for papers by Charles M. Baum Breakdown of academic impact, for papers by Apurva A. Desai
Rankless by CCL
2026